Strain Information | |
---|---|
Image | |
BRC No. | RBRC06054 |
Type | Targeted Mutation and Transgene![]() |
Species | Mus musculus |
Strain name | C57BL/6-Polk<tm3(mpolk)Csk> Tg(gptdelta)1Nmi |
Former Common name | inactivated Polk KI and gpt delta double transgenic mice |
H-2 Haplotype | |
ES Cell line | Not specified (ES cell) |
Background strain | |
Appearance | |
Strain development | Developed by Takehiko Nohmi, National Institute of Health Sciences. Inactivate Polk KI mice were generated by using C57BL/6N derived ES cells. The mutant mice were crossed with the gpt delta Tg mice (C57BL/6J background) (RBRC00158). C57BL/6J and C57BL/6N mixed background. |
Strain description | Inactivate Polk knock-in mice, in which Asp at position 197 and Glu at position 198 of exon 6 were replace with Ala, respectively. This mutant mice also have a gpt delta transgene that serves as a tool for assessing the mutagenicity of environmental chemicals. |
Colony maintenance | KI: Heterozygote x Wild-type; Tg: Carrier x Carrier |
References | In vivo evidence that DNA polymerase kappa is responsible for error-free bypass across DNA cross-links induced by mitomycin C. Takeiri A, Wada N A, Motoyama S, Matsuzaki K, Tateishi H, Matsumoto K, Niimi N, Sassa A, Gruz P, Masumura K, Yamada M, Mishima M, Jishage K I, Nohmi T DNA Repair, 24, 113-121(2014). 25303778 |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
Polk MGI:1349767 | polymerase (DNA directed), kappa | 13 | Polk<tm3(mpolk)Csk> | targeted mutation 3, Chugai Pharmaceutical Co, Ltd | |||
Polk MGI:1349767 | polymerase (DNA directed), kappa | 13 | Polk<tm3(mpolk)Csk> | targeted mutation 3, Chugai Pharmaceutical Co, Ltd | |||
cat | E. coli chloramphenicol acetyltransferase (CAT) | 17 | |||||
gpt Delta | guanine phosphoribosyltransferase | 17 | gpt Delta<Tg(gptdelta)1Nmi> MGI:3612991 | transgene insertion 1, Takehito Nohmi | |||
loxP | phage P1 loxP | 17 | loxP | ||||
loxP | phage P1 loxP | 17 | loxP | ||||
red/gam | lambda phage red/gam | 17 | red/gam |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | mouse inactivated polymerase k cDNA, mouse inactivated polymerase k genomic DNA, lambda phage red/gam Ori, P1 phage loxP sites, lambda 2001, E. coli gpt delta, E. coli chloramphenicol acetyltransferase (CAT) gene, chiC |
Research application | Cancer Research Cre/loxP system |
Specific Term and Conditions | Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must reach agreement on terms and conditions of use of the mice with the DEPOSITOR and its co-developer, Chugai Pharmaceutical Co., Ltd. (Contact person: Dr. Akira Takeiri, e-mail, takeiriakr@chugai-pharm.co.jp) and must obtain a prior written consent from them and, if necessary, shall enter into an agreement with them. |
Depositor | Takehiko Noumi (National Institute of Health Sciences) |
Strain Status | ![]() ![]() |
Strain Availability | Recovered litters from cryopreserved embryos (2 to 4 months) Cryopreserved sperm (within 1 month) Cryopreserved embryos (within 1 month) |
Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
---|
No Data |